Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.
Respiratory diseases account for approximately 10% of all hospital admissions in the United States. Pneumonia constitutes 35% of these cases, with an average length of stay (LOS) of 5.1 days. It is estimated that $8.4 billion to $10 billion of all annual US hospital expenditures are attributable to community-acquired pneumonia (CAP). As such, medical decisions, including empiric antibiotic choice, potentially exert an impact on hospital LOS and associated costs. In this review, we focus on the empiric antibiotic choices and associated costs of treatment for hospitalized patients with CAP, focusing on the use of fluoroquinolone therapy as recommended by the CAP guidelines.
Restrepo
Marcos I
MI
Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. restrepom@uthscsa.edu
Frei
Christopher R
CR
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000191:economics; D016527:Drug Costs; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay / Q000191:economics; D018942:Macrolides / Q000191:economics / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy* / Q000191:economics*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States; D047090:beta-Lactams / Q000191:economics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D018942:Macrolides; D047090:beta-Lactams